Prognostic role of vitamin d status and efficacy of vitamin D supplementation in cancer patients: a systematic review.

BACKGROUND Whether or not hypovitaminosis D can influence the prognosis of cancer patients and whether or not vitamin D (vitD) supplementation improves outcome remain controversial. DESIGN Studies evaluating the prognostic role of vitD and vitD receptor (VDR) in cancer patients and trials evaluating the efficacy of vitD administration on patient outcome were identified by a search of MEDLINE, EMBASE, ISI Web of Knowledge, and the Cochrane Library through June 2010. RESULTS Twenty-five studies were included. A negative prognostic role for low serum vitD level was observed in five cohort studies including patients with breast cancer (one study), colon cancer (two studies), prostate cancer (one study), and melanoma (one study), but not in two studies on non-small cell lung cancer and one study on breast cancer. Three of four studies showed that VDR(+) tumors carry a better prognosis than VDR(-) tumors, whereas VDR polymorphisms were significantly associated with prognosis in five of 10 studies. A significant interaction between serum vitD level and VDR polymorphism was observed in one study. Three randomized trials involving advanced prostate cancer patients explored the prognostic role of vitD supplementation. A meta-analysis of these trials showed no effect on survival (pooled risk ratio, 1.07; 95% confidence interval, CI, 0.93-1.23), with strong heterogeneity among studies. CONCLUSION Hypovitaminosis D seems to be associated with a worse prognosis in some cancers, but vitD supplementation failed to demonstrate a benefit in prostate cancer patients. The currently available evidence is insufficient to recommend vitD supplementation in cancer patients in clinical practice.

[1]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[2]  P. Albers,et al.  Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial. , 2010 .

[3]  S. Schulz,et al.  Immunohistochemical identification of the PTHR1 parathyroid hormone receptor in normal and neoplastic human tissues. , 2010, European journal of endocrinology.

[4]  N. Yanaihara,et al.  Vitamin D receptor polymorphisms and prognosis of patients with epithelial ovarian cancer , 2009, British Journal of Cancer.

[5]  M. Haberal,et al.  Clinical importance of vitamin D receptor gene polymorphism in invasive ductal carcinoma. , 2009, International surgery.

[6]  P. Goodwin,et al.  Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Ramanjaneya V. R. Mula,et al.  Parathyroid Hormone-Related Protein Regulates Cell Survival Pathways via Integrin α6β4-Mediated Activation of Phosphatidylinositol 3-Kinase/Akt Signaling , 2009, Molecular Cancer Research.

[8]  K. Pritchard,et al.  Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Goodwin.  Vitamin D in cancer patients: above all, do no harm. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Cremers,et al.  High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Tretli,et al.  Association between serum 25(OH)D and death from prostate cancer , 2009, British Journal of Cancer.

[12]  D. Neuberg,et al.  Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Altman,et al.  Chapter 8: Assessing risk of bias in included studies , 2008 .

[14]  D. Altman,et al.  Assessing Risk of Bias in Included Studies , 2008 .

[15]  Glenville Jones.  Pharmacokinetics of vitamin D toxicity. , 2008, The American journal of clinical nutrition.

[16]  J. Meyerhardt,et al.  Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. McNeel,et al.  Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer , 2008, Clinical Cancer Research.

[18]  Michael J. Pencina,et al.  Vitamin D Deficiency and Risk of Cardiovascular Disease , 2008, Circulation.

[19]  M. Haussler,et al.  Vitamin D Receptor: Key Roles in Bone Mineral Pathophysiology, Molecular Mechanism of Action, and Novel Nutritional Ligands , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  B. Graubard,et al.  Prospective study of serum vitamin D and cancer mortality in the United States. , 2007, Journal of the National Cancer Institute.

[21]  D. Trump.  Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators , 2007 .

[22]  M. Holick.  Vitamin D deficiency. , 2007, The New England journal of medicine.

[23]  C. Wongkham,et al.  Overexpression of vitamin D receptor indicates a good prognosis for cholangiocarcinoma , 2007, Cancer.

[24]  T. Fujioka,et al.  Vitamin D receptor gene polymorphisms are associated with increased risk and progression of renal cell carcinoma in a Japanese population , 2007, International journal of urology : official journal of the Japanese Urological Association.

[25]  D. Neuberg,et al.  Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C. Mathieu,et al.  Vitamin D and cancer , 2013, Cell cycle.

[27]  D. Neuberg,et al.  Polymorphisms of Vitamin D Receptor and Survival in Early-Stage Non–Small Cell Lung Cancer Patients , 2006, Cancer Epidemiology Biomarkers & Prevention.

[28]  E. Fernández,et al.  Vitamin D receptor polymorphisms and diseases. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[29]  A. Sugawara,et al.  Prognostic significance of vitamin D receptor and retinoid X receptor expression in renal cell carcinoma. , 2006, The Journal of urology.

[30]  M. Holick.  High prevalence of vitamin D inadequacy and implications for health. , 2006, Mayo Clinic proceedings.

[31]  W. Sakr,et al.  Vitamin D receptor gene polymorphisms and disease free survival after radical prostatectomy , 2004, The Prostate.

[32]  L. Potter,et al.  A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibilty and prognosis in malignant melanoma , 2004, British Journal of Cancer.

[33]  Johan Moan,et al.  Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway) , 2004, Cancer Causes & Control.

[34]  R. Wood,et al.  1,25-Dihydroxyvitamin D3 increases the expression of the CaT1 epithelial calcium channel in the Caco-2 human intestinal cell line , 2001, BMC Physiology.

[35]  H. Pols,et al.  Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1,25‐dihydroxyvitamin D3 , 2000, Clinical endocrinology.

[36]  P. Lips,et al.  An International Comparison of Serum 25-Hydroxyvitamin D Measurements , 1999, Osteoporosis International.

[37]  S. Wingren,et al.  Association of breast cancer progression with a vitamin D receptor gene polymorphism. South-East Sweden Breast Cancer Group. , 1999, Cancer research.

[38]  J. Hanfelt,et al.  Vitamin D receptor expression as a predictive marker of biological behavior in human colorectal cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  G. Stein,et al.  Distinct conformations of vitamin D receptor/retinoid X receptor-alpha heterodimers are specified by dinucleotide differences in the vitamin D-responsive elements of the osteocalcin and osteopontin genes. , 1996, Molecular endocrinology.

[40]  J. Stockman.  Common genetic determinants of vitamin D insufficiency: a genome-wide association study , 2012 .

[41]  J. L. Smith.  Serum 25-Hydroxyvitamin D3 Levels Are Associated With Breslow Thickness at Presentation and Survival From Melanoma , 2011 .

[42]  Z. Kırkalı,et al.  1,25 Dihydroxyvitamin D(3) receptor expression in superficial transitional cell carcinoma of the bladder: a possible prognostic factor? , 2005, European urology.

[43]  Pär Stattin,et al.  Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case‐control study in the Nordic countries , 2004, International journal of cancer.

[44]  T. Stamey,et al.  Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.